These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38160617)

  • 1. Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects.
    Cheng Z; Han T; Yao J; Wang K; Dong X; Yu F; Huang H; Han M; Liao Q; He S; Lyu W; Li Q
    Eur J Med Chem; 2024 Feb; 265():116065. PubMed ID: 38160617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.
    Shi HR; Zhu LQ; Wang SH; Liu XA; Tian Q; Zhang Q; Wang Q; Wang JZ
    J Neural Transm (Vienna); 2008 Jun; 115(6):879-88. PubMed ID: 18217188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of glycogen synthase kinase 3 in Alzheimer's disease.
    Cai Z; Zhao Y; Zhao B
    Curr Alzheimer Res; 2012 Sep; 9(7):864-79. PubMed ID: 22272620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
    Leroy K; Yilmaz Z; Brion JP
    Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease.
    Jin N; Yin X; Yu D; Cao M; Gong CX; Iqbal K; Ding F; Gu X; Liu F
    Sci Rep; 2015 Feb; 5():8187. PubMed ID: 25641096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors.
    Arafa RK; Elghazawy NH
    Adv Exp Med Biol; 2017; 1007():199-224. PubMed ID: 28840559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
    Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
    J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
    Takashima A
    J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.
    Farr SA; Ripley JL; Sultana R; Zhang Z; Niehoff ML; Platt TL; Murphy MP; Morley JE; Kumar V; Butterfield DA
    Free Radic Biol Med; 2014 Feb; 67():387-95. PubMed ID: 24355211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.
    Hurtado DE; Molina-Porcel L; Carroll JC; Macdonald C; Aboagye AK; Trojanowski JQ; Lee VM
    J Neurosci; 2012 May; 32(21):7392-402. PubMed ID: 22623685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GSK-3β and its Inhibitors in Alzheimer's Disease: A Recent Update.
    Chauhan N; Paliwal S; Jain S; Verma K; Paliwal S; Sharma S
    Mini Rev Med Chem; 2022; 22(22):2881-2895. PubMed ID: 35450523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
    Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
    Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells.
    Greco SJ; Sarkar S; Casadesus G; Zhu X; Smith MA; Ashford JW; Johnston JM; Tezapsidis N
    Neurosci Lett; 2009 May; 455(3):191-4. PubMed ID: 19429119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Amyloid: A Machine Learning-Driven Approach Reveals Properties of Potent GSK-3β Inhibitors Targeting Neurofibrillary Tangles.
    Nwadiugwu M; Onwuekwe I; Ezeanolue E; Deng H
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-
    Hartz RA; Ahuja VT; Sivaprakasam P; Xiao H; Krause CM; Clarke WJ; Kish K; Lewis H; Szapiel N; Ravirala R; Mutalik S; Nakmode D; Shah D; Burton CR; Macor JE; Dubowchik GM
    J Med Chem; 2023 Mar; 66(6):4231-4252. PubMed ID: 36950863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β.
    Amin J; Paquet C; Baker A; Asuni AA; Love S; Holmes C; Hugon J; Nicoll JA; Boche D
    Neuropathol Appl Neurobiol; 2015 Jun; 41(4):445-57. PubMed ID: 25486988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
    Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
    Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease.
    Sze CI; Su M; Pugazhenthi S; Jambal P; Hsu LJ; Heath J; Schultz L; Chang NS
    J Biol Chem; 2004 Jul; 279(29):30498-506. PubMed ID: 15126504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.